Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108024 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
A Phase 2 study of Seborrheic Keratosis, sponsored by DermBiont.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT06108024 is a Phase 2 study of Seborrheic Keratosis that is actively recruiting participants, run by DermBiont. The registered enrollment target is 60 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT06108024, a Phase 2 study of Seborrheic Keratosis, is actively recruiting participants, sponsored by DermBiont.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12-weeks post final application for a total of approximately 16-weeks of required participation in the study.
Conditions Studied
Interventions
- DRUG SM-020 gel 1.0%
- DRUG Vehicle gel
Study Locations (4)
Oregon
- Oregon Medical Research Center - Portland
- Oregon Dermatology and Research Center - Portland
Florida
- Driven Research LLC - Coral Gables
Minnesota
- Minnesota Clinical Study Center - New Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06108024
The ClinicalTrials.gov registry entry for NCT06108024 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DermBiont, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seborrheic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which SM-020 gel 1.0% is the first listed.
NCT06108024 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Oregon, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06108024 about?
NCT06108024 is a clinical study titled "A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis". The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investig...
What is the current status of trial NCT06108024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-11-06. Estimated completion is 2024-10-15.
What conditions does trial NCT06108024 study?
This clinical trial studies the following conditions: Seborrheic Keratosis.
What interventions are being tested in trial NCT06108024?
The interventions under investigation include: SM-020 gel 1.0% (DRUG), Vehicle gel (DRUG).
Who is sponsoring clinical trial NCT06108024?
This trial is sponsored by DermBiont, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108024 being conducted?
This trial has 4 study locations across Florida, Minnesota, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.